Latest News
-
Over 57 Million Could Be Clinically Eligible for GLP-1 Drugs
Over two in five (57.4 million) adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues.
-
First-Ever Government Negotiation Process for Drugs
This post for Health Affairs Forefront examines how the results of the first-ever Medicare drug price negotiations will generate savings for the government and for Medicare beneficiaries, and how candidates’ views on the issue could play a role in the upcoming elections and in the future of government negotiation.
-
What to Know About Medicare Part D Premiums
This brief explains provisions in the Inflation Reduction Act that are likely to shape Medicare Part D premiums for 2025, and how and why premiums might change. Actual premiums will not be known until September.
-
Beyond the Data by Drew Altman
In his regular Beyond the Data columns, CEO Drew Altman discusses what the data, polls, and journalism produced by KFF mean for policy and for people.